CoLucid Pharmaceuticals' (CLCD) SAMURAI Phase 3 Trial of Lasmiditan in Migraine Meets Primary and Secondary Endpoints
Tweet Send to a Friend
CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
